Published in:
01-09-2006 | Original Paper
Monitoring Cytochrome P-450 Activity During Rabeprazole Treatment in Patients with Gastresophageal Reflux Disease
Authors:
Edoardo G. Giannini, Vincenzo Savarino, Roberto Testa
Published in:
Digestive Diseases and Sciences
|
Issue 9/2006
Login to get access
Abstract
Proton pump inhibitors (PPIs) are the cornerstone in the treatment of gastresophageal reflux disease (GORD). PPIs are metabolized by the hepatic cytochrome P-450 enzymes (CYP-450). Rabeprazole is a PPI whose metabolism shows fewer interactions compared to other PPIs.
In this study we evaluated the influence of rabeprazole administration on hepatic CYP-450 activity as measured by the 13C-aminopyrine breath test (13C-ABT) in a group of patients with GORD.
13C-ABT was performed on five GORD patients both before and after 1 week of rabeprazole administration (20 mg, b.i.d.). Pretreatment 13C-ABT results were compared to posttreatment results. Pre- and posttreatment 13C-ABT results for patients were compared to those obtained in five controls who did the test twice, with a 1-week interval in between. Before treatment, the 13C-ABT results for the GORD patients did not significantly differ from those of healthy subjects. After treatment, we observed no significant modification of the 13C-ABT in GORD patients compared to pretreatment values (13C-ABT %dose/hr, 10.56±1.31 versus 11.17±0.88; 13C-ABT %cumulative dose, 8.08±1.11 versus 8.34±0.56). Posttreatment 13C-ABT results were not significantly different from those obtained in controls at weekly repetition of the test. In patients with GORD, 1-week, full-dose rabeprazole does not display any significant interactions with CYP-450 activity.